DE69819525D1 - Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol - Google Patents

Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol

Info

Publication number
DE69819525D1
DE69819525D1 DE69819525T DE69819525T DE69819525D1 DE 69819525 D1 DE69819525 D1 DE 69819525D1 DE 69819525 T DE69819525 T DE 69819525T DE 69819525 T DE69819525 T DE 69819525T DE 69819525 D1 DE69819525 D1 DE 69819525D1
Authority
DE
Germany
Prior art keywords
biavailability
taxol
oral
improving
acridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819525T
Other languages
English (en)
Other versions
DE69819525T2 (de
Inventor
Jan H M Schellens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69819525D1 publication Critical patent/DE69819525D1/de
Application granted granted Critical
Publication of DE69819525T2 publication Critical patent/DE69819525T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
DE69819525T 1997-09-05 1998-09-03 Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol Expired - Lifetime DE69819525T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9718903.9A GB9718903D0 (en) 1997-09-05 1997-09-05 Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9718903 1997-09-05
PCT/EP1998/005557 WO1999012570A2 (en) 1997-09-05 1998-09-03 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (2)

Publication Number Publication Date
DE69819525D1 true DE69819525D1 (de) 2003-12-11
DE69819525T2 DE69819525T2 (de) 2004-09-23

Family

ID=10818634

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819525T Expired - Lifetime DE69819525T2 (de) 1997-09-05 1998-09-03 Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol

Country Status (15)

Country Link
US (2) US6469022B1 (de)
EP (1) EP1009436B1 (de)
JP (2) JP4516688B2 (de)
KR (1) KR100579030B1 (de)
AT (1) ATE253360T1 (de)
AU (1) AU751085B2 (de)
BR (1) BR9812179A (de)
CA (1) CA2302568C (de)
DE (1) DE69819525T2 (de)
DK (1) DK1009436T3 (de)
ES (1) ES2210823T3 (de)
GB (1) GB9718903D0 (de)
PT (1) PT1009436E (de)
TR (1) TR200000586T2 (de)
WO (1) WO1999012570A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CA2290446C (en) * 1997-05-27 2008-01-29 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
ATE484295T1 (de) * 1999-05-17 2010-10-15 Cancer Res Ventures Ltd Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
EP1479382A1 (de) * 1999-06-18 2004-11-24 IVAX Research, Inc. Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
EP2792353B1 (de) 2003-05-22 2018-02-28 United Therapeutics Corporation Polymorph von Treprostinil-Diethanolaminsalz
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
EP1789128B1 (de) 2004-08-27 2018-05-09 STOCO 10 GmbH Elektronisch gesteuerte und ferngesteuerte tablette und system zur abgabe von mindestens einem medikament
JP2008521794A (ja) * 2004-11-29 2008-06-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも一の薬剤を輸送するための、少なくとも一のセンサを有する電子制御式の錠剤およびシステム
EP2254464B1 (de) * 2008-02-18 2017-01-04 Medimetrics Personalized Drug Delivery B.V. Verabreichung von wirkstoffen an einen patienten
JP5681861B2 (ja) * 2008-03-31 2015-03-11 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ センサを有する嚥下型カプセルを作成する方法
WO2009153739A1 (en) 2008-06-19 2009-12-23 Koninklijke Philips Electronics N.V. Device for delivery of powder like medication in a humid environment
WO2009156919A1 (en) * 2008-06-25 2009-12-30 Koninklijke Philips Electronics N.V. Electronic pill comprising a plurality of medicine reservoirs
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
CA2905720C (en) 2013-03-14 2021-10-19 United Therapeutics Corporation Solid forms of treprostinil
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100258C (en) * 1991-01-11 1999-12-14 Bernard Andre Dumaitre Acridine derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2290446C (en) * 1997-05-27 2008-01-29 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ATE484295T1 (de) * 1999-05-17 2010-10-15 Cancer Res Ventures Ltd Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Also Published As

Publication number Publication date
BR9812179A (pt) 2000-07-18
US6469022B1 (en) 2002-10-22
DK1009436T3 (da) 2004-03-08
JP2010059185A (ja) 2010-03-18
AU751085B2 (en) 2002-08-08
WO1999012570A3 (en) 1999-08-19
JP4516688B2 (ja) 2010-08-04
KR100579030B1 (ko) 2006-05-12
US20030013731A1 (en) 2003-01-16
ES2210823T3 (es) 2004-07-01
US6803373B2 (en) 2004-10-12
WO1999012570A2 (en) 1999-03-18
TR200000586T2 (tr) 2000-09-21
GB9718903D0 (en) 1997-11-12
JP2001515872A (ja) 2001-09-25
EP1009436B1 (de) 2003-11-05
KR20010023670A (ko) 2001-03-26
PT1009436E (pt) 2004-03-31
AU9439498A (en) 1999-03-29
CA2302568C (en) 2010-06-22
EP1009436A2 (de) 2000-06-21
DE69819525T2 (de) 2004-09-23
CA2302568A1 (en) 1999-03-18
ATE253360T1 (de) 2003-11-15

Similar Documents

Publication Publication Date Title
DE69819525D1 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
PT1193270E (pt) Pirrolobenzodiazepinas
DE60032780D1 (de) Tetrahydroquinolin-derivate
NO20011350L (no) 4-Karboksyaminosubstituerte 1,2,3,4-tetrahydrokinoliner som CETP inhibitorer
DE69809755D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalin derivate
DE122004000018I2 (de) 4"-substitutierte-9-deoxo-9a-aza-9a-homoerythromycin a derivate
DK1114033T3 (da) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE386024T1 (de) Arylkondensierte azapolycyclische derivate
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
CY1109276T1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
ATE237612T1 (de) Benzofuranderivate
BR9804027A (pt) Novos beta-ceto ésteres
DK0810220T3 (da) Arylacrylamidderivater som 5-HT1-agonister eller -antagonister
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
IT1295933B1 (it) 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
ATE250021T1 (de) Hydroxycyclopentanone
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
DE69611758D1 (de) N-1-carbocylalkyl derivate von lsd
DE60031269D1 (de) Halbsynthese von paclitaxel mit hilfe von dialkyldichlorsilanen
ATE220674T1 (de) 12h-dibenzo(d,g)(1,3)dioxocin derivate
SE9701438D0 (sv) A new process
NO971991L (no) Heterosyklus-substituerte propensyrederivater som NMDA-antagonister

Legal Events

Date Code Title Description
8364 No opposition during term of opposition